Association of multiple-sclerosis-related mortality with COVID-19 and other common infections: a multiple causes of death analysis

被引:3
|
作者
Fedeli, Ugo [1 ]
Amidei, Claudio Barbiellini [1 ]
Avossa, Francesco [1 ]
Schievano, Elena [1 ]
Kingwell, Elaine [2 ]
机构
[1] Azienda Zero, Epidemiol Dept, Padua, Veneto Region, Italy
[2] UCL, Res Dept Primary Care & Populat Hlth, London, England
关键词
COVID-19; epidemiology; mortality; multiple sclerosis; population-based study; POPULATION;
D O I
10.1111/ene.15912
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and purpose: People with multiple sclerosis (MS) suffer from higher infection-related mortality compared to the general population; however, sparse data are available on the increased risk of death associated with coronavirus disease 2019 (COVID-19) and other common types of infections. Methods: All mortality records and multiple-cause-of-death data in 2010-2021 of residents in the Veneto region (northeastern Italy) were extracted. Mention of specific infections was compared between death certificates reporting MS or not. Odds ratios (OR) with 95% confidence intervals (95% CI) were estimated by conditional logistic regression matching by age, sex and calendar year. The bimonthly averages of MS-related deaths in 2010-2019 were compared with those registered during the pandemic (2020-2021). Results: Of 580,015 deaths through 2010-2021, MS was mentioned in 850 cases (0.15%), 59.3% women. Influenza and pneumonia were reported in 18.4% of MS-related compared to 11.0% non-MS-related deaths (OR 2.72, 95% CI 2.28-3.25). The odds of mention of urinary tract infections was significantly greater in MS-related deaths of men (OR 8.16, 95% CI 5.23-12.7) than women (OR 3.03, 95% CI 1.82-5.02). Aspiration pneumonia, pressure ulcers/skin infections and sepsis were also significantly associated with MS-related deaths. Reporting of COVID-19 as a cause of death did not significantly differ between deaths with and without mention of MS (approximately 11% of both). However, compared to 2010-2019, peaks in MS-related deaths were observed during the pandemic waves. Conclusions: Infections continue to play a significant role in MS-related deaths, underlying the need to improve prevention and management strategies.
引用
收藏
页码:2870 / 2873
页数:4
相关论文
共 50 条
  • [41] Impact of vaccination on COVID-19 outcome in multiple sclerosis
    Bsteh, Gabriel
    Gradl, Christiane
    Heschl, Bettina
    Hegen, Harald
    Di Pauli, Franziska
    Assar, Hamid
    Leutmezer, Fritz
    Traxler, Gerhard
    Krajnc, Nik
    Zulehner, Gudrun
    Hiller, Maria-Sophia
    Rommer, Paulus
    Wipfler, Peter
    Guger, Michael
    Enzinger, Christian
    Berger, Thomas
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (11) : 3329 - 3336
  • [42] Multiple Sclerosis Management During the COVID-19 Pandemic
    Hollen, Chris
    Bernard, Jacqueline
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2022, 22 (08) : 537 - 543
  • [43] Multiple sclerosis management during the COVID-19 pandemic
    Moss, Brandon P.
    Mahajan, Kedar R.
    Bermel, Robert A.
    Hellisz, Kelsey
    Hua, Le H.
    Hudec, Timothy
    Husak, Scott
    McGinley, Marisa P.
    Ontaneda, Daniel
    Wang, Zhini
    Weber, Malory
    Tagliani, Paula
    Cardenas-Robledo, Simon
    Zabalza, Ana
    Arrambide, Georgina
    Carbonell-Mirabent, Pere
    Rodriguez-Barranco, Marta
    Sastre-Garriga, Jaume
    Tintore, Mar
    Montalban, Xavier
    Douglas, Morgan
    Ogbuokiri, Esther
    Aravidis, Berna
    Cohen, Jeffrey A.
    Mowry, Ellen M.
    Fitzgerald, Kathryn C.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (10) : 1163 - 1171
  • [44] Multiple Sclerosis immunotherapies and COVID-19 mortality: an analysis of the FDA Adverse Event Reporting System
    Pistor, Maximilian
    Hoepner, Robert
    Hoepner, Andreas G. F.
    Lin, Yanan
    Jung, Simon
    Bassetti, Claudio L.
    Chan, Andrew
    Salmen, Anke
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2022, 15
  • [45] COVID-19 severity is associated with worsened neurological outcomes in multiple sclerosis and related disorders
    Conway, Sarah E.
    Healy, Brian C.
    Zurawski, Jonathan
    Severson, Christopher
    Kaplan, Tamara
    Stazzone, Lynn
    Galetta, Kristin
    Chitnis, Tanuja
    Houtchens, Maria K.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 63
  • [46] Key points to keep in mind related to COVID-19 vaccines in people with multiple sclerosis
    Galleguillos, Lorna
    Alonso, Ricardo
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 54
  • [47] Experiences Related to the Injection of COVID-19 Vaccines in Patients with Multiple Sclerosis: A Qualitative Study
    Rahmatian, Aryoobarzan
    Jamshidbeigi, Yousef
    Molavi, Ali
    Salimi, Ebrahim
    ARCHIVES OF NEUROSCIENCE, 2023, 10 (03)
  • [48] Multiple Sclerosis and COVID-19: An Overview on Risk, Severity, and Association With Disease Modifying Therapies
    Hollist, Mary
    Hollist, Abraham
    Au, Katherine
    Betts, Colton
    Kirmani, Maha
    Kirmani, Maaida
    Armour, Benjamin
    Udeh, Mercy C.
    Kirmani, Batool F.
    NEUROSCIENCE INSIGHTS, 2024, 19
  • [49] Can COVID-19 exacerbate multiple sclerosis symptoms? A case series analysis
    Michelena, Gloria
    Casas, Magdalena
    Barbara Eizaguirre, Maria
    Cecilia Pita, Maria
    Cohen, Leila
    Alonso, Ricardo
    Garcea, Orlando
    Silva, Berenice A.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 57
  • [50] Growing burden of sepsis-related mortality in northeastern Italy: a multiple causes of death analysis
    Ugo Fedeli
    Pasquale Piccinni
    Elena Schievano
    Mario Saugo
    Giampietro Pellizzer
    BMC Infectious Diseases, 16